SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

30 May 2022 Evaluate
The sales moved up 28.12% to Rs. 1762.78 millions for the March 2022 quarter as compared to Rs. 1375.83 millions during the year-ago period.A slender decline of -9.54% was recorded to Rs. 214.27  millions from Rs. 236.88 millions in the corresponding previous quarter.Operating profit for the quarter ended March 2022 decreased to 345.16 millions as compared to 386.87 millions of corresponding quarter ended March 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 1762.78 1375.83 28.12 6582.89 5995.48 9.80 6582.89 5995.48 9.80
Other Income 76.48 119.08 -35.77 422.51 311.56 35.61 422.51 311.56 35.61
PBIDT 345.16 386.87 -10.78 1559.66 1448.68 7.66 1559.66 1448.68 7.66
Interest 12.78 21.38 -40.22 37.95 53.45 -29.00 37.95 53.45 -29.00
PBDT 332.38 365.49 -9.06 1521.71 1395.23 9.07 1521.71 1395.23 9.07
Depreciation 46.08 41.45 11.17 176.63 151.93 16.26 176.63 151.93 16.26
PBT 286.30 324.04 -11.65 1345.08 1243.30 8.19 1345.08 1243.30 8.19
TAX 72.03 87.16 -17.36 305.20 259.49 17.62 305.20 259.49 17.62
Deferred Tax -11.26 10.58 -206.43 5.04 -22.39 -122.51 5.04 -22.39 -122.51
PAT 214.27 236.88 -9.54 1039.88 983.81 5.70 1039.88 983.81 5.70
Equity 409.31 409.31 0.00 409.31 409.31 0.00 409.31 409.31 0.00
PBIDTM(%) 19.58 28.12 -30.37 23.69 24.16 -1.95 23.69 24.16 -1.95

Marksans Pharma Share Price

179.55 -0.95 (-0.53%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×